Abstract
BACKGROUND: The BRAF V600E mutation (BRAF mut) in papillary thyroid cancer (PTC) has been associated with poor response to therapy with 131I in patien......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
